Leopold Sellner

2.4k total citations
57 papers, 1.6k citations indexed

About

Leopold Sellner is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Leopold Sellner has authored 57 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 25 papers in Molecular Biology and 17 papers in Genetics. Recurrent topics in Leopold Sellner's work include CAR-T cell therapy research (24 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Virus-based gene therapy research (13 papers). Leopold Sellner is often cited by papers focused on CAR-T cell therapy research (24 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Virus-based gene therapy research (13 papers). Leopold Sellner collaborates with scholars based in Germany, China and United States. Leopold Sellner's co-authors include Michael Schmitt, Sophia Stock, Thorsten Zenz, Peter Dreger, Andriy Mokhir, Steffen Daum, Maria‐Luisa Schubert, Anita Schmitt, Carsten Müller‐Tidow and Lei Wang and has published in prestigious journals such as Angewandte Chemie International Edition, Blood and Bioinformatics.

In The Last Decade

Leopold Sellner

57 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leopold Sellner Germany 24 806 678 321 268 250 57 1.6k
Challice L. Bonifant United States 19 1.2k 1.5× 751 1.1× 573 1.8× 299 1.1× 92 0.4× 57 2.0k
Puja Sapra United States 28 1.1k 1.4× 1.5k 2.2× 400 1.2× 454 1.7× 214 0.9× 62 3.1k
Marlon R. Veldwijk Germany 24 448 0.6× 585 0.9× 162 0.5× 207 0.8× 124 0.5× 60 1.5k
Shang‐Fan Yu United States 22 833 1.0× 929 1.4× 280 0.9× 205 0.8× 101 0.4× 45 1.7k
Quang‐Dé Nguyen United Kingdom 25 642 0.8× 1.0k 1.5× 267 0.8× 215 0.8× 125 0.5× 53 2.1k
Pamela A. Trail United States 29 1.5k 1.8× 1.7k 2.5× 474 1.5× 248 0.9× 265 1.1× 61 3.7k
Dennis R. Benjamin United States 18 1.2k 1.5× 1.0k 1.5× 306 1.0× 109 0.4× 200 0.8× 41 2.3k
Michaela Feuring‐Buske Germany 25 499 0.6× 1.1k 1.7× 342 1.1× 231 0.9× 76 0.3× 76 2.2k
Nicole M. Okeley United States 22 1.4k 1.8× 1.2k 1.8× 316 1.0× 166 0.6× 443 1.8× 38 2.8k
Elaine Westrick United States 19 620 0.8× 937 1.4× 136 0.4× 456 1.7× 370 1.5× 28 2.2k

Countries citing papers authored by Leopold Sellner

Since Specialization
Citations

This map shows the geographic impact of Leopold Sellner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leopold Sellner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leopold Sellner more than expected).

Fields of papers citing papers by Leopold Sellner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leopold Sellner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leopold Sellner. The network helps show where Leopold Sellner may publish in the future.

Co-authorship network of co-authors of Leopold Sellner

This figure shows the co-authorship network connecting the top 25 collaborators of Leopold Sellner. A scholar is included among the top collaborators of Leopold Sellner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leopold Sellner. Leopold Sellner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Palomba, M. Lia, Isabelle Rivière, Devanjan Sikder, et al.. (2023). A Phase I Study of CD19‐targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B‐cell Lymphoma. Hematological Oncology. 41(S2). 527–528. 1 indexed citations
2.
Gong, Wenjie, Lei Wang, Maria‐Luisa Schubert, et al.. (2022). HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma. Biomedicines. 10(2). 373–373. 4 indexed citations
3.
Roessner, Philipp M., Laura Llaó Cid, Tobias Roider, et al.. (2021). EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia. Leukemia. 35(8). 2311–2324. 30 indexed citations
4.
Gong, Wenjie, Lei Wang, Sophia Stock, et al.. (2021). Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells. Cells. 10(1). 152–152. 4 indexed citations
5.
Xu, Hong‐Gui, Viktor Reshetnikov, Leoni A. Kunz‐Schughart, et al.. (2021). Intracellular Amplifiers of Reactive Oxygen Species Affecting Mitochondria as Radiosensitizers. Cancers. 14(1). 208–208. 10 indexed citations
6.
Yoo, Keun-Young, Sophia Stock, Lei Wang, et al.. (2020). Ibrutinib for improved chimeric antigen receptor T‐cell production for chronic lymphocytic leukemia patients. International Journal of Cancer. 148(2). 419–428. 52 indexed citations
7.
Sellner, Leopold, Nicola Giesen, Maria‐Luisa Schubert, et al.. (2020). B‐cell maturation antigen‐specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives. International Journal of Cancer. 147(8). 2029–2041. 9 indexed citations
8.
Yang, Mingya, Lei Wang, Ming Ni, et al.. (2020). Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells. Frontiers in Immunology. 11. 608167–608167. 32 indexed citations
9.
Lukas, Marina, Britta Velten, Leopold Sellner, et al.. (2020). Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies. Leukemia. 34(11). 2934–2950. 17 indexed citations
10.
Yoo, Keun-Young, Yibin Liu, Lei Wang, et al.. (2019). Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies. International Journal of Molecular Sciences. 20(10). 2469–2469. 15 indexed citations
11.
Stock, Sophia, Michael Schmitt, & Leopold Sellner. (2019). Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy. International Journal of Molecular Sciences. 20(24). 6223–6223. 106 indexed citations
12.
Wang, Lei, Wenjie Gong, Sanmei Wang, et al.. (2019). Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells. Cytotherapy. 21(5). 566–578. 17 indexed citations
13.
14.
Gdynia, Georg, Tadeusz Robak, Jürgen Kopitz, et al.. (2018). Distinct Activities of Glycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immunotherapy. EBioMedicine. 32. 125–133. 4 indexed citations
15.
Lee, Kwang Seok, Jennifer Hüllein, Marina Lukas, et al.. (2018). Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma. Scientific Reports. 8(1). 12046–12046. 21 indexed citations
16.
Stock, Sophia, Jean‐Marc Hoffmann, Maria‐Luisa Schubert, et al.. (2018). Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells. Human Gene Therapy. 29(10). 1167–1182. 21 indexed citations
17.
Wu, Bian, Mikołaj Słabicki, Leopold Sellner, et al.. (2017). MED12 mutations and NOTCH signalling in chronic lymphocytic leukaemia. British Journal of Haematology. 179(3). 421–429. 27 indexed citations
18.
Bystrý, Vojtěch, Tomáš Reigl, Adam Krejčí, et al.. (2017). ARResT/Interrogate IG/TR NGSデータに対するインタラクティブ免疫プロファイラ. Bioinformatics. 33(3). 437. 1 indexed citations
19.
Sellner, Leopold, Monika Brüggemann, Henrik Knecht, et al.. (2016). GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses. Bone Marrow Transplantation. 52(4). 544–551. 25 indexed citations
20.
Hotz‐Wagenblatt, Agnes, Jennifer Hüllein, Leopold Sellner, et al.. (2015). p53-dependent non-coding RNA networks in chronic lymphocytic leukemia. Leukemia. 29(10). 2015–2023. 140 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Challice L. Bonifant Breakdown of academic impact, for papers by Puja Sapra Breakdown of academic impact, for papers by Marlon R. Veldwijk Breakdown of academic impact, for papers by Shang‐Fan Yu Breakdown of academic impact, for papers by Quang‐Dé Nguyen Breakdown of academic impact, for papers by Pamela A. Trail Breakdown of academic impact, for papers by Dennis R. Benjamin Breakdown of academic impact, for papers by Michaela Feuring‐Buske Breakdown of academic impact, for papers by Nicole M. Okeley Breakdown of academic impact, for papers by Elaine Westrick
Rankless by CCL
2026